Henrik Blou, Gubra CEO
November 13, 2024 02:27 PM EST
R&D

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Kyle LaHucik

Senior Reporter

The amylin field is heat­ing up ahead of No­vo Nordisk’s much-an­tic­i­pat­ed Ca­griSe­ma read­out lat­er this year.

On Wednes­day, Gubra said peo­ple …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times